Changing Treatment Landscape for Follicular Lymphoma

February 2, 2017

This video examines the evolution in treatment and survival outcomes for patients with follicular lymphoma and highlights trials testing newer agents such as immunotherapies in this population.

In this video, Nathan H. Fowler, MD, of MD Anderson Cancer Center, discusses the evolution in treatment for patients with follicular lymphoma and the improvement in survival outcomes since the introduction of the monoclonal antibody rituximab in this setting.

Dr. Fowler also reviews the standard treatment for these patients, the role of novel antibodies following chemotherapy failure, and looks ahead at newer agents such as checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy currently in trials for follicular lymphoma.